178 high-risk patients experienced 90%+ lipoprotein(a) level reductions in a Phase 2 trial of Silence Therapeutics' zerlasiran, with no serious safety concerns.
Silence Therapeutics' zerlasiran (SLN360) showed significant reductions of 90% or more in lipoprotein(a) (Lp(a)) levels in 178 high-risk patients in a Phase 2 trial. The siRNA agent was well-tolerated with no serious safety concerns. The study's positive 48-week data supports zerlasiran's potential in treating cardiovascular disease, as Lp(a) has been linked to increased cardiovascular risk.
June 20, 2024
4 Articles